Novartis distances itself from Pixuvri
This article was originally published in Scrip
Executive Summary
Novartis will not be exercising its option for Cell Therapeutics' non-Hodgkin's lymphoma drug Pixuvri (pixantrone), which it has held since 2006, despite the product finally winning round Europe's reimbursement authorities. It is also returning rights to Opaxio (paclitaxel poliglumex), which it acquired under the same agreement (scripintelligence.com, 22 September 2006). Novartis has failed to show any real interest in either drug since signing the deal.